Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Ivemend
IVEMEND 150 mg powder for solution for infusion. · Abschnitt 4.5 · PDF-Seite 8
HOS-117449 · Präparat HOS-094609
Warfarin
In patients on chronic warfarin therapy, the prothrombin time (INR) should be monitored closely
during treatment with and for 14 days following the use of IVEMEND for the prevention of
chemotherapy induced nausea and vomiting (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-05T14:57:00Z · SHA-256 9e19bc1fa93d788029c9702424aacb9622fe408d4db1dbe0bc9e0ad1d449f179 · Passage 16768ea3e59589003f49b214e8bb76b5ce882e778d907d882c0fba07dbb15153 · Zeichen 6261–6514 im Abschnitt
Wechselwirkungen · Tasigna
Tasigna 50 mg hard capsules Tasigna 150 mg hard capsules Tasigna 200 mg hard capsules · Abschnitt 4.5 · PDF-Seite 11
HOS-118213 · Präparat HOS-094783
A single-dose drug-drug interaction study in healthy volunteers with 25 mg warfarin, a sensitive
CYP2C9 substrate, and 800 mg nilotinib did not result in any changes in warfarin pharmacokinetic
parameters or warfarin pharmacodynamics measured as prothrombin time (PT) and international
normalised ratio (INR). There are no steady-state data. This study suggests that a clinically meaningful
drug-drug interaction between nilotinib and warfarin is less likely up to a dose of 25 mg of warfarin.
Due to lack of steady-state data, control of warfarin pharmacodynamic markers (INR or PT) following
initiation of nilotinib therapy (at least during the first 2 weeks) is recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-17T17:21:00Z · SHA-256 efb2ca2c5c7d9a0e740759217e71ff7f08cf3763f8c41f5c02f5d10733d67b3a · Passage 8ca0afb28cbfa443abc53e281f6f96834e6db1f41e13d85865205d7617f120f4 · Zeichen 3479–4156 im Abschnitt
Wechselwirkungen · Volibris
Volibris 2.5 mg film-coated tablets Volibris 5 mg film-coated tablets Volibris 10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-118980 · Präparat HOS-094889
Ambrisentan had no effects on the steady-state pharmacokinetics and anti-coagulant activity of
warfarin in a healthy volunteer study (see section 5.2). Warfarin also had no clinically significant
effects on the pharmacokinetics of ambrisentan. In addition, in patients, ambrisentan had no overall
effect on the weekly warfarin-type anticoagulant dose, prothrombin time (PT) and international
normalised ratio (INR).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-22T14:55:00Z · SHA-256 5c01ef1f81a8078355d1d9b164dc55e270b4c22e60736bc4ee1b622689a8bc09 · Passage 022b23f1512dbfe1a6f8a571848d5076365952e4b046813d3f63122a07b0a475 · Zeichen 3201–3616 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-120052 · Präparat HOS-095079
Warfarin
Converting patients from the vitamin K antagonist warfarin (INR 2.0 to 3.0) to rivaroxaban (20 mg) or
from rivaroxaban (20 mg) to warfarin (INR 2.0 to 3.0) increased prothrombin time/INR (Neoplastin)
more than additively (individual INR values up to 12 may be observed), whereas effects on aPTT,
inhibition of factor Xa activity and endogenous thrombin potential were additive.
If it is desired to test the pharmacodynamic effects of rivaroxaban during the conversion period, anti-
factor Xa activity, PiCT, and Heptest can be used as these tests were not affected by warfarin. On the
fourth day after the last dose of warfarin, all tests (including PT, aPTT, inhibition of factor Xa activity
and ETP) reflected only the effect of rivaroxaban.
If it is desired to test the pharmacodynamic effects of warfarin during the conversion period, INR
measurement can be used at the Ctrough of rivaroxaban (24 hours after the previous intake of
rivaroxaban) as this test is minimally affected by rivaroxaban at this time point.
No pharmacokinetic interaction was observed between warfarin and rivaroxaban.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): thrombin (HOS-120053) vitamin K (HOS-091176) prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 918b34bc287cd79c46210954d3607f98f667e8a3885a27c80133167679b563d1 · Zeichen 4377–5482 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 35–36
HOS-120084 · Präparat HOS-095079
35
Warfarin
Converting patients from the vitamin K antagonist warfarin (INR 2.0 to 3.0) to rivaroxaban (20 mg) or
from rivaroxaban (20 mg) to warfarin (INR 2.0 to 3.0) increased prothrombin time/INR (Neoplastin)
more than additively (individual INR values up to 12 may be observed), whereas effects on aPTT,
inhibition of factor Xa activity and endogenous thrombin potential were additive.
If it is desired to test the pharmacodynamic effects of rivaroxaban during the conversion period, anti-
factor Xa activity, PiCT, and Heptest can be used as these tests were not affected by warfarin. On the
fourth day after the last dose of warfarin, all tests (including PT, aPTT, inhibition of factor Xa activity
and ETP) reflected only the effect of rivaroxaban.
If it is desired to test the pharmacodynamic effects of warfarin during the conversion period, INR
measurement can be used at the Ctrough of rivaroxaban (24 hours after the previous intake of
rivaroxaban) as this test is minimally affected by rivaroxaban at this time point.
No pharmacokinetic interaction was observed between warfarin and rivaroxaban.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): thrombin (HOS-120053) vitamin K (HOS-091176) prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 3eff9c5ee0153bba5f74e257f41052f4172ca58adb2badf7a92c77d31768ee07 · Zeichen 4432–5541 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 15 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 62–63
HOS-120115 · Präparat HOS-095079
62
Warfarin
Converting patients from the vitamin K antagonist warfarin (INR 2.0 to 3.0) to rivaroxaban (20 mg) or
from rivaroxaban (20 mg) to warfarin (INR 2.0 to 3.0) increased prothrombin time/INR (Neoplastin)
more than additively (individual INR values up to 12 may be observed), whereas effects on aPTT,
inhibition of factor Xa activity and endogenous thrombin potential were additive.
If it is desired to test the pharmacodynamic effects of rivaroxaban during the conversion period, anti-
factor Xa activity, PiCT, and Heptest can be used as these tests were not affected by warfarin. On the
fourth day after the last dose of warfarin, all tests (including PT, aPTT, inhibition of factor Xa activity
and ETP) reflected only the effect of rivaroxaban.
If it is desired to test the pharmacodynamic effects of warfarin during the conversion period, INR
measurement can be used at the Ctrough of rivaroxaban (24 hours after the previous intake of
rivaroxaban) as this test is minimally affected by rivaroxaban at this time point.
No pharmacokinetic interaction was observed between warfarin and rivaroxaban.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): thrombin (HOS-120053) vitamin K (HOS-091176) prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage f0d8430536a876d8383030c2c936de5109133a48a28dbb7eb5a43ea7a405bed7 · Zeichen 4656–5765 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 94–95
HOS-120147 · Präparat HOS-095079
94
Warfarin
Converting patients from the vitamin K antagonist warfarin (INR 2.0 to 3.0) to rivaroxaban (20 mg) or
from rivaroxaban (20 mg) to warfarin (INR 2.0 to 3.0) increased prothrombin time/INR (Neoplastin)
more than additively (individual INR values up to 12 may be observed), whereas effects on aPTT,
inhibition of factor Xa activity and endogenous thrombin potential were additive.
If it is desired to test the pharmacodynamic effects of rivaroxaban during the conversion period, anti-
factor Xa activity, PiCT, and Heptest can be used as these tests were not affected by warfarin. On the
fourth day after the last dose of warfarin, all tests (including PT, aPTT, inhibition of factor Xa activity
and ETP) reflected only the effect of rivaroxaban.
If it is desired to test the pharmacodynamic effects of warfarin during the conversion period, INR
measurement can be used at the Ctrough of rivaroxaban (24 hours after the previous intake of
rivaroxaban) as this test is minimally affected by rivaroxaban at this time point.
No pharmacokinetic interaction was observed between warfarin and rivaroxaban.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): thrombin (HOS-120053) vitamin K (HOS-091176) prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 40c825faec769e4cc712a061f78c9a461b2423ec5424b2c3b1729363eaa91e6d · Zeichen 4656–5765 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 15 mg film-coated tablets Xarelto 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 124
HOS-120178 · Präparat HOS-095079
Warfarin
Converting patients from the vitamin K antagonist warfarin (INR 2.0 to 3.0) to rivaroxaban (20 mg) or
from rivaroxaban (20 mg) to warfarin (INR 2.0 to 3.0) increased prothrombin time/INR (Neoplastin)
more than additively (individual INR values up to 12 may be observed), whereas effects on aPTT,
inhibition of factor Xa activity and endogenous thrombin potential were additive.
If it is desired to test the pharmacodynamic effects of rivaroxaban during the conversion period, anti-
factor Xa activity, PiCT, and Heptest can be used as these tests were not affected by warfarin. On the
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): thrombin (HOS-120053) vitamin K (HOS-091176) prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 78879878babc715b75c8eb22053b6cc502d841f427972d5890443eb06a316265 · Zeichen 4379–4972 im Abschnitt
Wechselwirkungen · Xarelto
Xarelto 1 mg/mL granules for oral suspension · Abschnitt 4.5 · PDF-Seite 149
HOS-120209 · Präparat HOS-095079
Warfarin
Converting patients from the vitamin K antagonist warfarin (INR 2.0 to 3.0) to rivaroxaban (20 mg) or
from rivaroxaban (20 mg) to warfarin (INR 2.0 to 3.0) increased prothrombin time/INR (Neoplastin)
more than additively (individual INR values up to 12 may be observed), whereas effects on aPTT,
inhibition of factor Xa activity and endogenous thrombin potential were additive.
If it is desired to test the pharmacodynamic effects of rivaroxaban during the conversion period, anti-
factor Xa activity, PiCT, and Heptest can be used as these tests were not affected by warfarin. On the
fourth day after the last dose of warfarin, all tests (including PT, aPTT, inhibition of factor Xa activity
and ETP) reflected only the effect of rivaroxaban.
If it is desired to test the pharmacodynamic effects of warfarin during the conversion period, INR
measurement can be used at the Ctrough of rivaroxaban (24 hours after the previous intake of
rivaroxaban) as this test is minimally affected by rivaroxaban at this time point.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): thrombin (HOS-120053) vitamin K (HOS-091176) prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T13:29:00Z · SHA-256 296cd19bd9d543e8a553e31f26d947abea5c7cc81862818289ca4c4ece9a3aa9 · Passage 705980ebbf64d4d705e0c8f30997c6ea88377854c50d09a7072bf1e10aec9555 · Zeichen 4601–5628 im Abschnitt
Wechselwirkungen · Pantozol Control
PANTOZOL Control 20 mg gastro-resistant tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-121271 · Präparat HOS-095311
Although no interaction during concomitant administration of phenprocoumon or warfarin has been
observed in clinical pharmacokinetic studies, a few isolated cases of changes in International
Normalised Ratio (INR) have been reported during concomitant treatment in the post-marketing
period. Therefore, in patients treated with coumarin anticoagulants (e.g., phenprocoumon or warfarin),
monitoring of prothrombin time/INR is recommended after initiation, termination or during irregular
use of pantoprazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): coumarin (HOS-088372) phenprocoumon (HOS-091031) prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-05-25T09:40:00Z · SHA-256 74b810d41ae676f9b6d4a8f91ac3b9f2a6bb2766634c7fe3fe9823d5e550ca6b · Passage 7a6a7807c668d0252e96a04dbeb0b6455b753840823a47206df713e6135e14f7 · Zeichen 532–1039 im Abschnitt
Wechselwirkungen · Adcirca (previously Tadalafil Lilly)
ADCIRCA 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-210090 · Präparat HOS-154449
CYP2C9 substrates (e.g.R-warfarin)
Tadalafil (10 mg and 20 mg) had no clinically significant effect on exposure (AUC) to S-warfarin or
R-warfarin (CYP2C9 substrate), nor did tadalafil affect changes in prothrombin time induced by
warfarin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T15:17:00Z · SHA-256 f45503711a580d9fd5973be63b2c67b7830a1e53d77892c603581b2f6ee084ab · Passage 0e070897fcee89ead64be94e0ac24a54fa2015da62aeda763dc5c099924db8f1 · Zeichen 4195–4434 im Abschnitt
Wechselwirkungen · Adcirca (previously Tadalafil Lilly)
ADCIRCA 2 mg/mL oral suspension · Abschnitt 4.5 · PDF-Seite 24
HOS-210142 · Präparat HOS-154449
CYP2C9 substrates (e.g.R-warfarin)
Tadalafil (10 mg and 20 mg) had no clinically significant effect on exposure (AUC) to S-warfarin or
R-warfarin (CYP2C9 substrate), nor did tadalafil affect changes in prothrombin time induced by
warfarin.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T15:17:00Z · SHA-256 f45503711a580d9fd5973be63b2c67b7830a1e53d77892c603581b2f6ee084ab · Passage 0e070897fcee89ead64be94e0ac24a54fa2015da62aeda763dc5c099924db8f1 · Zeichen 4191–4430 im Abschnitt
Wechselwirkungen · Nimvastid
Nimvastid 1.5 mg hard capsules Nimvastid 3 mg hard capsules Nimvastid 4.5 mg hard capsules Nimvastid 6 mg hard capsules · Abschnitt 4.5 · PDF-Seite 6
HOS-210196 · Präparat HOS-154463
No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam
or fluoxetine in studies in healthy volunteers. The increase in prothrombin time induced by warfarin is
not affected by administration of rivastigmine. No untoward effects on cardiac conduction were
observed following concomitant administration of digoxin and rivastigmine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): digoxin (HOS-086172) diazepam (HOS-085904) prothrombin (HOS-085093) fluoxetine (HOS-085946) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-17T12:40:00Z · SHA-256 7977a2e740f93e10c6c1dbfee473c4849225e6d1d135ce94de2c91c369b45b63 · Passage bd1d97bec127ae96022cba55f4ca875123452150396aa27221df94b0684fb025 · Zeichen 1749–2119 im Abschnitt
Wechselwirkungen · Nimvastid
Nimvastid 1.5 mg orodispersible tablets Nimvastid 3 mg orodispersible tablets Nimvastid 4.5 mg orodispersible tablets Nimvastid 6 mg orodispersible tablets · Abschnitt 4.5 · PDF-Seite 21
HOS-210219 · Präparat HOS-154463
No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam
or fluoxetine in studies in healthy volunteers. The increase in prothrombin time induced by warfarin is
not affected by administration of rivastigmine. No untoward effects on cardiac conduction were
observed following concomitant administration of digoxin and rivastigmine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): digoxin (HOS-086172) diazepam (HOS-085904) prothrombin (HOS-085093) fluoxetine (HOS-085946) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-17T12:40:00Z · SHA-256 7977a2e740f93e10c6c1dbfee473c4849225e6d1d135ce94de2c91c369b45b63 · Passage bd1d97bec127ae96022cba55f4ca875123452150396aa27221df94b0684fb025 · Zeichen 1697–2067 im Abschnitt
Wechselwirkungen · Raloxifene Teva
Raloxifene Teva 60 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 4
HOS-210828 · Präparat HOS-154595
Co-administration of raloxifene and warfarin does not alter the pharmacokinetics of either compound.
However, modest decreases in the prothrombin time have been observed, and if raloxifene is given
concurrently with warfarin or other coumarin derivatives, the prothrombin time should be monitored.
Effects on prothrombin time may develop over several weeks if raloxifene treatment is started in
patients who are already on coumarin anticoagulant therapy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): coumarin (HOS-088372) prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2021-09-27T11:30:00Z · SHA-256 bbf6706a7418bb5343336909f5773d58520cc2fd4c0b1b303b9821080fd9b117 · Passage 2556e9a0a7480af571f18431f24cb81cad90fdd90b9f9e501814e503a2ddc870 · Zeichen 163–617 im Abschnitt
Wechselwirkungen · Controloc Control
CONTROLOC Control 20 mg gastro-resistant tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-121766 · Präparat HOS-095429
Although no interaction during concomitant administration of phenprocoumon or warfarin has been
observed in clinical pharmacokinetic studies, a few isolated cases of changes in International
Normalised Ratio (INR) have been reported during concomitant treatment in the post-marketing
period. Therefore, in patients treated with coumarin anticoagulants (e.g., phenprocoumon or warfarin),
monitoring of prothrombin time/INR is recommended after initiation, termination or during irregular
use of pantoprazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): coumarin (HOS-088372) phenprocoumon (HOS-091031) prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-05-25T09:08:00Z · SHA-256 e7bfcc80e0d744a3ae6dc7e45d026433d68d865a95e0e5185c1771cd63eb461e · Passage 7a6a7807c668d0252e96a04dbeb0b6455b753840823a47206df713e6135e14f7 · Zeichen 533–1040 im Abschnitt
Wechselwirkungen · Somac Control
SOMAC Control 20 mg gastro-resistant tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-211877 · Präparat HOS-154776
Although no interaction during concomitant administration of phenprocoumon or warfarin has been
observed in clinical pharmacokinetic studies, a few isolated cases of changes in International
Normalised Ratio (INR) have been reported during concomitant treatment in the post-marketing
period. Therefore, in patients treated with coumarin anticoagulants (e.g., phenprocoumon or warfarin),
monitoring of prothrombin time/INR is recommended after initiation, termination or during irregular
use of pantoprazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): coumarin (HOS-088372) phenprocoumon (HOS-091031) prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-05-24T09:32:00Z · SHA-256 6d8f7d6ff1a05f6ec91f06d93ac70bd03edb677073b9513b2006a963eea1d696 · Passage 7a6a7807c668d0252e96a04dbeb0b6455b753840823a47206df713e6135e14f7 · Zeichen 529–1036 im Abschnitt
Wechselwirkungen · Leflunomide Zentiva (previously Leflunomide Winthrop)
Leflunomide Zentiva 10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-122341 · Präparat HOS-095511
There have been case reports of increased prothrombin time, when leflunomide and warfarin were
co-administered. A pharmacodynamics interaction with warfarin was observed with A771726 in a
clinical pharmacology study (see below). Therefore, when warfarin or another coumarin anticoagulant
is co-administered, close international normalised ratio (INR) follow-up and monitoring is
recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): coumarin (HOS-088372) prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T17:27:00Z · SHA-256 bed6a472e84572491a61af1acb52b0f05e60157fe2f2f53c93e4e488c7c80e1b · Passage a9093abb34837a3778a55369457217a2a4cc322f92c132008c1f7b63f90d4051 · Zeichen 1604–1995 im Abschnitt
Wechselwirkungen · Leflunomide Zentiva (previously Leflunomide Winthrop)
Leflunomide Zentiva 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 25
HOS-122420 · Präparat HOS-095511
There have been case reports of increased prothrombin time, when leflunomide and warfarin were
co-administered. A pharmacodynamics interaction with warfarin was observed with A771726 in a
clinical pharmacology study (see below). Therefore, when warfarin or another coumarin anticoagulant
is co-administered, close international normalised ratio (INR) follow-up and monitoring is
recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): coumarin (HOS-088372) prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T17:27:00Z · SHA-256 bed6a472e84572491a61af1acb52b0f05e60157fe2f2f53c93e4e488c7c80e1b · Passage a9093abb34837a3778a55369457217a2a4cc322f92c132008c1f7b63f90d4051 · Zeichen 1605–1996 im Abschnitt
Wechselwirkungen · Leflunomide Zentiva (previously Leflunomide Winthrop)
Leflunomide Zentiva 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 42
HOS-122480 · Präparat HOS-095511
There have been case reports of increased prothrombin time, when leflunomide and warfarin were
co-administered. A pharmacodynamics interaction with warfarin was observed with A771726 in a
clinical pharmacology study (see below). Therefore, when warfarin or another coumarin anticoagulant
is co-administered, close international normalised ratio (INR) follow-up and monitoring is
recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): coumarin (HOS-088372) prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-22T17:27:00Z · SHA-256 bed6a472e84572491a61af1acb52b0f05e60157fe2f2f53c93e4e488c7c80e1b · Passage a9093abb34837a3778a55369457217a2a4cc322f92c132008c1f7b63f90d4051 · Zeichen 1606–1997 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.